Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

ra to confirm that amantadine, originally developed as an antiviral and now commonly used to address side effects of L-dopa therapy, could help Parkinson's patients.

"The differentiated profile observed in this Phase II trial is interesting and intriguing as there are currently no other drugs with this combination of therapeutic effects," said Professor Rascol. "Particularly if the therapeutic effect on non-levodopa sensitive symptoms can be confirmed in the Phase IIb and subsequent trials, the compound would address a very important unmet medical need for all mid-to-late stage patients developing postural disturbances, and could represent a significant advance in approaches to Parkinson's disease."

Also being presented at the conference is a poster on the results of FP0011 in a MPTP macaque monkey model of Parkinson's disease, by Dr. Jonathan Brotchie, CEO of Atuka Ltd. of Toronto, Canada. In this trial, monkeys that have developed dyskinesia from the administration of L-dopa to treat Parkinsonian symptoms from the neurotoxin, MPTP, were administered FP0011. FP0011 reduced the severity of L-dopa-induced dyskinesia while extending the duration of the anti-Parkinsonian action of L-dopa.

"Unlike other drugs on the market that increase the duration of L-dopa action, FP0011 did not exacerbate the problem of dyskinesia," said Dr. Brotchie. "If these effects were seen in patients, then over the course of a day such an action could significantly enhance the quality of life of people with advanced Parkinson's disease."

Commenting on these presentations, Thomas Seoh, CEO of Faust noted that: "These mutually supportive data in the Phase IIa trial and the MPTP monkey trial presented at this conference strongly support the further clinical development of FP0011 as an adjunctive therapy to L-dopa in patients with established motor complications. We look forward to confirming and extending these results in larger trials for Parkinson's patients. Ultima
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... YORK , August 21, 2014 ... Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license ... software for plant breeders and researchers, today is ... a joint venture with Seach Ltd, a leading ... formed to research and develop new breeds of ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2
... from the,Barbara Ann Karmanos Cancer Institute in ... or resveratrol to conventional chemotherapy,could be effective ... cancer,cells. The poster presentation was delivered at ... Meeting in San Diego, CA., ( ...
... used to treat,inflammatory conditions but can increase the risk of osteoporotic ... patients on long-term therapy at risk(1,2), - Study of more ... with Reclast than with risedronate, a current established therapy(3) ... of ...
Cached Medicine Technology:Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids 2Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids 3Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids 4Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids 5Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids 6
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... Health System and The University of Texas MD Anderson ... a new level of specialized breast screening at a ... Houston area. , Starting in late November, MD Anderson ... services for five of Memorial Hermann,s 10 breast care ... and Sugar Land. , Over time, the network will ...
(Date:8/21/2014)... only is eating better and exercising healthy for people with ... year, a new study finds. The study, led by ... Forest Baptist Medical Center in Winston-Salem, N.C., included more ... Participants ranged in age from 45 to 76, ... program" focused on diet and exercise, or to a standard ...
(Date:8/21/2014)... August 21, 2014 Transvaginal mesh ... Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. ... 14th, the Court has established new stipulated evidence ... handling, division, storage and preservation. (In re C.R. ...
(Date:8/21/2014)... FRANCISCO Aug. 21, 2014 Researchers in the ... congenital cataracts can quickly and accurately diagnose a number ... a study published online today in ... Ophthalmology. Using a single test, doctors were able ... on their mutations reducing the time and money spent ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2
... People who suffer cardiac arrests and then receive coronary ... brain damage compared with those who don,t have the ... School of Medicine researchers. The study, published in the ... Medicine and now available online, showed that patient ...
... March 31 Responding to negative impacts on clinician productivity and ... Inc. ( www.usercentric.com ) - a ... service offering specifically for health care organizations (HCOs) : ... clinicians are struggling to adopt EHRs because they are too time-consuming ...
... Research (IADR) announces Dr. Anthony Fauci, director, National Institute ... Institutes of Health in Bethesda, Md., USA as 2009 ... at the 87th General Session & Exhibition in Miami, ... Dr. Fauci became director of NIAID, where he oversees ...
... of Cosmetic Surgery 2008 Procedural Survey shows a 2% ... the first time in several years, male cosmetic surgery ... of Cosmetic Surgery (AACS), a leader in the cosmetic ... survey reveals that males are cutting back on cosmetic ...
... The not-for-profit LENA Foundation is putting forth a ... Society of Research in Child Development (SRCD). At the ... one poster will be presented based on findings using ... SRCD is a great opportunity for our colleagues to ...
... FRAMINGHAM, Mass., March 31 Courion(R) Corporation ... today announced that Kurt Johnson, vice president of corporate ... leader of technical management, will deliver a presentation entitled ... Compliance," at the HIMSS 09 Annual Conference ...
Cached Medicine News:Health News:Coronary angiography may improve outcomes for cardiac arrest patients 2Health News:Coronary angiography may improve outcomes for cardiac arrest patients 3Health News:User Centric to Address EHR Usability With New Service Offering 2Health News:User Centric to Address EHR Usability With New Service Offering 3Health News:Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3Health News:Courion and Alegent Health to Discuss HIPAA and Next-Generation Healthcare Portals at HIMSS 09 Annual Conference and Exhibition 2
... the ProtecPoint Exit Alerting System, instantly ... and assets (e.g. medical equipment), with ... facility. With this form of exit ... savings, operating efficiencies, and overall peace ...
... Context-sensitive medicine is the ability of ... in pre-determined ways based on what is ... the associations a Radianse indoor positioning solution ... and it requires identity, location and time ...
... ability to track the movement of ... assets can be done. VerdaSee's "intellishelvess" ... Continuous cycle counting is possible with ... (RFID) technology makes this possible. VerdaSee ...
Agility has delivered a RFID-enabled mobile asset management program....
Medicine Products: